Ulcerative Colitis
Ulcerative Colitis (UC) is a long-term inflammatory bowel disease where the immune system attacks the colon and rectum, resulting in inflammation, ulcers, and symptoms like abdominal pain, diarrhea with blood, weight loss, fever, and anemia, with potential complications including megacolon, and an increased risk of colon cancer. Symptoms typically occur intermittently with periods of remission.
Health Outcomes
- Accelerated Colitis Recovery
- Accurate Enumeration of Viable Probiotic Bacteria
- Achieved Histological Remission
- Achieved Inflammation Homeostasis
- Activated Intestinal Immune Response
- Activated Systemic Immunoreactivity in Peyer's Patches
- Activation of Peyer's Patches Plasmacytoid Dendritic Cells
- Adjusted Immune Function
- Adjusted Intestinal Microbiota Abundance
- Alleviated Constipation
- Alleviated Histopathological Changes in the Colon
- Alleviated Intestinal Damage
- Alleviated Intestinal Disease
- Alleviated Rectal Bleeding
- Altered Bifidobacterial Population
- Altered Bifidobacterium Profile
- Altered Colonic Microbial Communities
- Altered Cytokine Levels in Jejunal Mucosa
- Altered Dominant Intestinal Bacterial Composition
- Altered Dominant Microbial Community
- Altered Expression of Immune Products
- Altered Expression of Immune-Related Genes
- Altered Faecal Microbiota Profile
- Altered Fecal Butyrate Levels
- Altered Fecal Metabolite Levels
- Altered Gastrointestinal Microbial Communities
- Altered Gastrointestinal Microbiome Composition
- Altered Gut Metabolome
- Altered Gut Microbial Transcriptomic Response
- Altered IFN-γ Levels
- Altered IgA Concentration in Ileal Flushes
- Altered Immune Response
- Altered Intestinal Mucosa Morphology
- Altered Intestinal Transit
- Altered Microbial Phyla Abundance
- Altered Microbial Profile
- Altered NF-kappaB Signaling
- Altered Serum Immune Protein Levels
- Altered Spirochaetes Abundance in Pig Microbiota
- Altered Stool Microbiota Profile
- Altered Systemic Immune Response
- Attenuated Enterocyte Injury
- Attenuated Gut Dysbiosis
- Balanced Gut Microbiome
- Balanced Intestinal Microflora
- Balanced Treg/Th17 Regulation
- Baseline Intestinal Permeability
- Binding to Goblet Cell Mucus
- Changed Magnesium Level
- Changed Stool Consistency
- Changes in Inflammatory Markers
- Colonization of Fibrolytic Bacteria
- Colonization of the Intestine
- Corrected Gut Microbiota Disorders
- Counterbalanced Gut Dysbiosis
- Decreased Digestive Enzyme Activities in Ileum
- Decreased Naïve CD45RA+ T Helper Cells
- Decreased Roseburia faecis Relative Abundance
- Decreased TNF-α Production in Immune Cells
- Decreased TNFα Levels
- Delayed Onset of Colitis
- Disrupted Gut Microbiota Distribution
- Disrupted Mucosal Barrier
- Diversified B-Cell Populations in the Colon
- Diversified B-cell Populations in the Lamina Propria
- Duration of Symptoms
- Effective Treatment of Crohn's Disease
- Elevated Bifidobacterium Levels
- Elevated ERK Levels in Intestinal Stem Cells
- Elevated Fecal Acidic Steroid Levels
- Elevated Fecal IgA Levels
- Elevated Fecal Lactate Levels
- Elevated IL-10 Levels
- Elevated IL-22 Levels
- Elevated IgA Levels in Milk
- Elevated Interleukin-10 Levels
- Elevated Plasma Lysozyme Levels
- Elevated Serum IFN-γ Levels
- Elevated Serum Metabolites in Response to Inflammation
- Elevated Serum TNF-α Levels
- Elevated Serum Total Ig Levels
- Elevated β-Catenin Levels in Intestinal Stem Cells
- Enhanced Abundance of Beneficial Bacterial Species
- Enhanced Adherence to Intestinal Epithelial Cells
- Enhanced Adhesion to Colon Cells
- Enhanced Adhesion to Enterocyte-like Cells
- Enhanced Adjuvanticity
- Enhanced Anti-Inflammatory Cytokine Production
- Enhanced Anti-Inflammatory Cytokine Secretion
- Enhanced Anti-inflammatory Cytokine Expression During Healing
- Enhanced Anti-inflammatory Properties
- Enhanced Anti-inflammatory Response
- Enhanced Antigen Uptake
- Enhanced Barrier Integrity
- Enhanced Beneficial Bacteria in Intestinal Microbiota
- Enhanced Beneficial Gut Microbiota
- Enhanced Beneficial Microbial Populations
- Enhanced Bifidobacterial Diversity
- Enhanced Colon Bacterial Diversity
- Enhanced Colonic Mucosa Adhesion
- Enhanced Colorectal Homeostasis
- Enhanced Cytokine Production
- Enhanced Dendritic Cell Recruitment in Intestinal Villi
- Enhanced Dendritic Cell-T Cell Interaction
- Enhanced Differentiation of Intestinal Stem Cells into Goblet Cells
- Enhanced Diversity of Protective Bifidobacterial Populations
- Enhanced Functional Gene Presence in Small Intestine
- Enhanced GLP-2 Secretion
- Enhanced Gastrointestinal Stress Resistance
- Enhanced Gastrointestinal Survival
- Enhanced Goblet Cell Regeneration
- Enhanced Growth of Beneficial Gut Bacteria
- Enhanced Gut Flora Composition
- Enhanced Gut Health
- Enhanced Gut Microbiome Health
- Enhanced Gut Microbiota Diversity
- Enhanced Gut Microbiota Maturation
- Enhanced Gut Microbiota Stability
- Enhanced Gut Probiotic Levels
- Enhanced Host-Microbe Balance
- Enhanced Immune Function Post-Cessation
- Enhanced Immune Modulation
- Enhanced Immune Regulation
- Enhanced Immune Response
- Enhanced Immune Signaling Molecule Production
- Enhanced Immunomodulation
- Enhanced Immunomodulatory Function
- Enhanced Immunoregulatory Molecule Activity
- Enhanced Inflammation Resolution
- Enhanced Inflammatory Response
- Enhanced Interleukin-10 Production
- Enhanced Intestinal Barrier Function
- Enhanced Intestinal Cell Adhesion
- Enhanced Intestinal Defense Maturation
- Enhanced Intestinal Development
- Enhanced Intestinal Epithelial Cell Adhesion
- Enhanced Intestinal Epithelial Cell Growth
- Enhanced Intestinal Epithelial Maturation
- Enhanced Intestinal Immunity
- Enhanced Intestinal Innate Mucosal Immunity
- Enhanced Intestinal Integrity
- Enhanced Intestinal MUC2 Secretion
- Enhanced Intestinal Microbiota Maturation
- Enhanced Intestinal Morphometry
- Enhanced Intestinal Mucin Production
- Enhanced Intestinal Mucosal Cell Protection
- Enhanced Intestinal Repair Processes
- Enhanced Jejunal Immune Response
- Enhanced Leukocyte Recruitment
- Enhanced Lymphocyte Proliferation
- Enhanced Metabolism in Small Intestine Microbiota
- Enhanced Mitochondrial Fitness of Intestinal Regulatory T-cells
- Enhanced Mucosal Immune Response
- Enhanced Mucosal Protection
- Enhanced Phenotypic Maturation of Dendritic Cells
- Enhanced Prebiotic Activity
- Enhanced Pro-Inflammatory Cytokine Response
- Enhanced Probiotic Activity
- Enhanced Probiotic Bacteria Count
- Enhanced Probiotic Growth
- Enhanced Probiotic Gut Adhesion
- Enhanced Regulatory Immune System Development
- Enhanced Regulatory T Cell Development
- Enhanced Regulatory T Cell Function
- Enhanced Regulatory T-Cells in Mesenteric Lymphoid Nodes
- Enhanced SCFA Production
- Enhanced Serum Metabolite Levels Against Inflammation
- Enhanced Small Intestine Metabolic Function
- Enhanced Spleen Cell Proliferative Response
- Enhanced Suppressive Function of Intestinal Tregs
- Enhanced Survival under Gastrointestinal Stress
- Enhanced T Cell Activation
- Enhanced T- and B-Lymphocyte Proliferation
- Enhanced Tight Junction Integrity
- Enhanced Treg Cell Differentiation
- Gastrointestinal Survival
- Gastrointestinal Tract Persistence
- Germination of Probiotics in Small Intestine
- Gut Colonization by Saccharomyces boulardii
- Gut Localization of Lactobacillus brevis
- Healed Colitis
- Healthy Gut Microbiome
- Immune Response to Rotavirus Vaccine Antigen
- Impaired Intestinal Barrier Function
- Improved Abdominal Pain
- Improved Abdominal Pain in Colitis Patients
- Improved Abundance of Beneficial Bacteria
- Improved Adherence to Enterocytes
- Improved Alpha Diversity of Intestinal Microbiota
- Improved Antigen-Specific IgA Secretion
- Improved Antioxidant and Anti-Inflammatory Response
- Improved Beneficial Intestinal Bacteria
- Improved Beneficial Intestinal Microbiota
- Improved Bifidobacterium-Dominated Microbiota
- Improved Bifidogenic Response
- Improved Bloating
- Improved Bowel Function
- Improved Bowel Habit Satisfaction
- Improved Bowel Movement Frequency
- Improved Bowel Movements
- Improved Bristol Stool Type
- Improved CD4- CD8+ low T Cell Percentage in Ileum
- Improved Clinical Disease Activity
- Improved Clinical Outcomes in Colitis
- Improved Colitis
- Improved Colitis Survival
- Improved Colitis Symptoms
- Improved Colon Cancer Symptoms
- Improved Colon Pain
- Improved Colonic Antioxidant Levels
- Improved Colonic Delivery
- Improved Colonic Delivery Feasibility of Oxygen-Sensitive Probiotics
- Improved Colonic Health
- Improved Colonic Histology
- Improved Colonic Histopathology
- Improved Colonic Immune Response
- Improved Colonic Length
- Improved Colonic Microbial Diversity
- Improved Colonic Microenvironment
- Improved Colonic Mucosal Integrity
- Improved Colonization of Gastrointestinal Tract by Lactobacilli
- Improved Community Diversity of Intestinal Microbiota
- Improved Crohn's Disease Symptoms
- Improved Crypt Hyperplasia
- Improved Cytokine Levels
- Improved Cytokine Production
- Improved Degradability of Acid Detergent Fiber
- Improved Diarrhea Symptoms
- Improved Digestibility of Neutral Detergent Fiber
- Improved Digestive Function
- Improved Digestive Health
- Improved Digestive Performance
- Improved Digestive Symptoms
- Improved Digestive Viability
- Improved Disease Activity Index Score
- Improved Diversity of Gut Microbiota
- Improved Effectiveness in Inflammatory Bowel Disease
- Improved Endotoxemia-related Inflammation
- Improved Enteral Nutrition Uptake
- Improved Epithelial Barrier Function
- Improved Epithelial Barrier Integrity
- Improved Epithelial Permeability
- Improved Faecal Dry Matter
- Improved Fecal Acetate Recovery
- Improved Fecal Lactobacillus Count
- Improved Fecal Microbiota
- Improved Fecal Score
- Improved Fecal Short-Chain Fatty Acid Levels
- Improved Fecal Water Content
- Improved Flatus
- Improved Formula Tolerance
- Improved Functional Genes in Intestinal Microbiota
- Improved Gastrointestinal Function
- Improved Gastrointestinal Inflammation
- Improved Gastrointestinal Microbiome Balance
- Improved Gastrointestinal Resilience
- Improved Gastrointestinal Resistance
- Improved Gastrointestinal Score
- Improved Gastrointestinal Survival
- Improved Gastrointestinal Symptom Management
- Improved Gastrointestinal Symptom Rating Scale Score
- Improved Gastrointestinal Symptom Relief
- Improved Gastrointestinal Symptom Score
- Improved Gastrointestinal Symptoms
- Improved Gastrointestinal Tolerance
- Improved Gastrointestinal Transit Survival
- Improved Gastrointestinal Viability
- Improved Gastrointestinal Well-Being
- Improved General GI Health Status
- Improved General Tolerance
- Improved Gross Morphology of Intestinal Tissue
- Improved Growth of Beneficial Bacteria
- Improved Gut Adhesion
- Improved Gut Bacterial Diversity
- Improved Gut Barrier Function
- Improved Gut Barrier Morphology
- Improved Gut Flora Diversity
- Improved Gut Flora Modulation
- Improved Gut Health
- Improved Gut Health (Lower Faecal pH)
- Improved Gut Homeostasis
- Improved Gut Immunity
- Improved Gut Inflammation
- Improved Gut Integrity
- Improved Gut Microbial Alpha Diversity
- Improved Gut Microbial Balance
- Improved Gut Microbial Dysbiosis
- Improved Gut Microbial Persistence
- Improved Gut Microbial Population
- Improved Gut Microbial Richness
- Improved Gut Microbiome
- Improved Gut Microbiome Diversity
- Improved Gut Microbiome Function
- Improved Gut Microbiome Recovery
- Improved Gut Microbiota
- Improved Gut Microbiota Balance
- Improved Gut Microbiota Composition
- Improved Gut Microbiota Composition in Small Intestine
- Improved Gut Microbiota Distribution
- Improved Gut Microbiota Diversity
- Improved Gut Microbiota Fermentation
- Improved Gut Microbiota Growth Medium Suitability
- Improved Gut Microbiota Homeostasis
- Improved Gut Microbiota Richness
- Improved Gut Microbiota Structure
- Improved Gut Microbiota-Related Disease Support in Ulcerative Colitis
- Improved Gut Microbiota-Related Pathways
- Improved Gut Morphology
- Improved Gut Mucosa Health
- Improved Gut Mucosal Histology
- Improved Gut Permeability
- Improved Gut Protection
- Improved Gut Repair
- Improved Gut Resilience
- Improved Gut Stress Resistance
- Improved Gut Tolerance
- Improved Histological Healing
- Improved Host-Gut Microbiota Related Molecular Adaptation
- Improved Host-Probiotic Interaction
- Improved IBD Remission Maintenance
- Improved IL-10/TNF-α Ratio
- Improved IgA Production
- Improved Ileal Histomorphometry
- Improved Immune Balance
- Improved Immune Cell Chemotactic Activity
- Improved Immune Parameters
- Improved Immune Tolerance
- Improved Immune-Related Symptoms
- Improved Immunoglobulin Levels
- Improved Immunologic Barrier Function
- Improved Immunological Status of Mucosa
- Improved Immunomodulation
- Improved Inflammation Homeostasis
- Improved Inflammation Levels
- Improved Inflammatory Biomarkers
- Improved Inflammatory Profile
- Improved Inflammatory Regulation
- Improved Inflammatory Response
- Improved Inflammatory Status
- Improved Interleukin-10 Levels
- Improved Intestinal Alkaline Phosphatase Activity
- Improved Intestinal Barrier
- Improved Intestinal Barrier Function
- Improved Intestinal Barrier Integrity
- Improved Intestinal Cell Adhesion
- Improved Intestinal Cell Integrity
- Improved Intestinal Cell Proliferation
- Improved Intestinal Cell Viability
- Improved Intestinal Crypt Survival
- Improved Intestinal Cytokine Function
- Improved Intestinal Defense
- Improved Intestinal Defense Mechanism
- Improved Intestinal Development
- Improved Intestinal Digestive Enzyme Activity
- Improved Intestinal Environment
- Improved Intestinal Epithelial Barrier
- Improved Intestinal Epithelial Barrier Function
- Improved Intestinal Epithelial Cell Function
- Improved Intestinal Epithelial Intercellular Integrity
- Improved Intestinal Epithelial Permeability
- Improved Intestinal Epithelium Recovery
- Improved Intestinal Function
- Improved Intestinal Health
- Improved Intestinal Health from Zinc Deficiency Prevention
- Improved Intestinal Histology
- Improved Intestinal Histomorphology
- Improved Intestinal Histopathology
- Improved Intestinal Immune Barrier
- Improved Intestinal Immune Response
- Improved Intestinal Immune Responsiveness
- Improved Intestinal Immunity
- Improved Intestinal Immunomodulatory Function
- Improved Intestinal Injury
- Improved Intestinal Innate Immunity
- Improved Intestinal Integrity
- Improved Intestinal LAB Viability
- Improved Intestinal Metabolism
- Improved Intestinal Microbial Composition
- Improved Intestinal Microbiota
- Improved Intestinal Microbiota Balance
- Improved Intestinal Microbiota Health
- Improved Intestinal Microenvironment
- Improved Intestinal Microflora
- Improved Intestinal Morphology
- Improved Intestinal Morphometry
- Improved Intestinal Mucosa Architecture
- Improved Intestinal Mucosal Health
- Improved Intestinal Mucosal Histology
- Improved Intestinal Mucosal Immunity
- Improved Intestinal Mucosal Repair
- Improved Intestinal Resistance to Salmonella Typhimurium
- Improved Intestinal Structure
- Improved Intestinal Survival
- Improved Intestinal Villi Epithelium Integrity
- Improved Intestinal Villus Height
- Improved Intestinal Villus Morphology
- Improved Iron Absorption
- Improved Iron Levels
- Improved Irritable Bowel Syndrome Symptoms
- Improved Jejunal Health
- Improved Jejunal Morphology
- Improved Macroscopic Colonic Damage
- Improved Management of Colitis
- Improved Microbial Community Composition
- Improved Microbial Diversity
- Improved Microbiota Activity
- Improved Microbiota Diversity
- Improved Microbiota Profile
- Improved Microflora Composition
- Improved Mucosal Barrier Function
- Improved Mucosal Healing
- Improved Niche Colonization
- Improved Nutrient Absorption
- Improved Nutrient Digestibility
- Improved Oral Tolerance
- Improved Overall Gastrointestinal Symptoms
- Improved Overall Symptom Score
- Improved Peripheral Blood Lymphocyte Proliferation
- Improved Prebiotic Index
- Improved Probiotic Product Stability
- Improved Proliferative Capacity of Intestinal Cells
- Improved Protein Absorption
- Improved Recovery From Colitis
- Improved Recovery of Intestinal Flora
- Improved Regulatory T Cell Function
- Improved Remission
- Improved Remission Rate
- Improved Responder Rate
- Improved Safety and Tolerability of Probiotic Consumption
- Improved Serum Protein Status
- Improved Short-Chain Fatty Acid Production
- Improved Short-Chain Fatty Acids Levels
- Improved Spontaneous Bowel Movements
- Improved Stability of Gut Microbiota
- Improved Starch Degradation Potential
- Improved Stool Characteristics
- Improved Stool Formation
- Improved Stool Frequency
- Improved Stool Quality
- Improved Stool Softness
- Improved Strain-Level Competitive Fitness
- Improved Survival Through GI Passage
- Improved Symptom Relief
- Improved Tight Junction Protein Localization
- Improved Tissue Pathology
- Improved Tolerance to Intestinal Conditions
- Improved Tolerance to Lactobacillus rhamnosus PRSF-L477
- Improved Treg/Th-17 Balance
- Improved Ulcerative Colitis
- Improved Viability of Lactic Acid Bacteria
- Improved Water Absorption
- Increase in Bifidobacterium lactis HN019
- Increased Abundance of Beneficial Gut Genera
- Increased Abundance of Beneficial Microorganisms
- Increased Abundance of Beneficial SCFAs-Producing Bacteria
- Increased Abundance of Bifidobacterium
- Increased Abundance of Goblet Cells
- Increased Abundance of Peptostreptococcaceae
- Increased Acetic Acid in Stool
- Increased Activation of Intestinal Stem Cells
- Increased Activation of Regulatory T Cells
- Increased Adhesion to Enterocytes
- Increased Adhesion to Epithelia
- Increased Alpha Diversity of Jejunal Mucosa-Associated Microbiota
- Increased Anti-Inflammatory Bacteria Abundance
- Increased Anti-Inflammatory Cytokine IL-10
- Increased Anti-Inflammatory Cytokine Levels
- Increased Anti-Inflammatory Cytokines in the Small Intestine
- Increased Anti-Inflammatory Immune Cell Populations
- Increased Anti-inflammatory Cytokines
- Increased Anti-inflammatory to Pro-inflammatory Cytokine Ratio
- Increased Antigen-Presenting Cell Activation
- Increased Autophagy in Intestinal Epithelial Cells
- Increased B Cell Populations
- Increased Bacterial Translocation
- Increased Bacteroides Levels in the Intestine
- Increased Beneficial Bacteria Levels
- Increased Beneficial Bacterial Counts
- Increased Beneficial Bacterial Species
- Increased Beneficial Bifidobacteria
- Increased Beneficial Gut Microbiota Abundance
- Increased Beneficial Indole Derivative Production
- Increased Beneficial Intestinal Metabolites
- Increased Bifidobacteria Levels in Intestine
- Increased Bifidobacteria in Colon
- Increased Bifidobacterial Populations in Feces
- Increased Bifidobacterium Animalis in Stool
- Increased Bifidobacterium Breve Count in Stool
- Increased Bifidobacterium Diversity
- Increased Bifidobacterium Dominance in Faecal Microbiota
- Increased Bifidobacterium Levels
- Increased Bifidobacterium Levels in Feces
- Increased Bifidobacterium lactis GCL2505 Intestinal Proliferation
- Increased Bifidobacterium lactis Proliferation in the Intestine
- Increased Bifidobacterium longum Relative Abundance
- Increased Bifidobacterium-Dominated Gut Microbiota
- Increased Bowel Movement Frequency
- Increased Bowel Movements
- Increased Bowel Mucosal Mass
- Increased Butyrate Concentration
- Increased Butyrate Concentrations in Colonic Digesta
- Increased Butyrate Levels
- Increased Butyrate Production
- Increased Butyrate-Producing Gut Bacteria
- Increased Butyric Acid Levels
- Increased CCL-20 Levels
- Increased CD103+ Dendritic Cell Count
- Increased CD3d Expression in Colon During Weaning
- Increased CD4-Positive T-Lymphocytes in Ileal Epithelium
- Increased Colitis Severity
- Increased Colon Barrier Biomarkers
- Increased Colon Inflammation
- Increased Colon Lactobacilli
- Increased Colonic Butyric Acid Concentrations
- Increased Colonic Lactobacilli Levels
- Increased Colonic Mucosa Adhesion
- Increased Colonic Mucosal Glutathione S-Transferase Levels
- Increased Colonization of S. thermophilus
- Increased Commensal Lactobacilli Levels
- Increased Cytokine Production
- Increased Cytokine Production in Peripheral Blood Mononuclear Cells
- Increased Cytokine Response
- Increased Cytokine Secretion
- Increased Defecation Frequency
- Increased Diamine Oxidase Secretion
- Increased Diarrhea Incidence
- Increased Digestive Problem
- Increased Duodenal Inflammation
- Increased Expression of Glial Cell-Derived Neurotrophic Factor in the Colon
- Increased Expression of Human Beta Defensin-2
- Increased Faecal Carboxylic Acid Concentration
- Increased Faecalibacterium prausnitzii Population
- Increased Fecal Acetate Levels
- Increased Fecal Acetic Acid Concentration
- Increased Fecal Acidic Steroid Levels
- Increased Fecal Bifidobacterial Populations
- Increased Fecal Bile Acid Levels
- Increased Fecal Butyrate Levels
- Increased Fecal Butyric Acid Concentration
- Increased Fecal Calprotectin Levels
- Increased Fecal Cell Persistence
- Increased Fecal Concentration of Propionic Acid
- Increased Fecal Energy Excretion
- Increased Fecal Excretion
- Increased Fecal IgA Concentration
- Increased Fecal Immunoglobulin A Concentrations
- Increased Fecal Immunoglobulin A Levels
- Increased Fecal Immunological Biomarkers
- Increased Fecal Lactate Concentration
- Increased Fecal Lactate Levels
- Increased Fecal Lactic Acid
- Increased Fecal Lactic Acid Bacteria Concentration
- Increased Fecal Lactic Acid Bacteria Counts
- Increased Fecal Lactobacillus Count
- Increased Fecal Lactobacillus Paracasei Levels
- Increased Fecal Output
- Increased Fecal Probiotic Bacteria
- Increased Fecal Propionic Acid Levels
- Increased Fecal Score
- Increased Fecal Water Content
- Increased Fiber Carbohydrate Degradation Rate
- Increased Foxp3 Protein Levels
- Increased Frequency of Complete Spontaneous Bowel Movements
- Increased Frequency of Loose or Watery Stools
- Increased Functional Gene Abundance in Small Intestine
- Increased Functional Genes in Caeca
- Increased GLP-2 Release
- Increased Gastrointestinal Tract Colonization
- Increased Genetic Diversity of Lactic Acid Bacteria Population
- Increased Gut Beneficial Microbes
- Increased Gut Lactic Acid Bacteria Count
- Increased Gut Levels of Lactobacillus and Lactococcus
- Increased Gut Microbial Growth
- Increased Gut Microbial Supplementation
- Increased Gut Microbiota Dissimilarity
- Increased IFN-gamma Secretion from Naïve T Cells
- Increased IFN-γ Levels
- Increased IL-10 Levels
- Increased IL-10 in Mucosal Tissue
- Increased IL-10/TNF-α Ratio in Intestinal Fluids
- Increased IL-12 Levels
- Increased IL-12 Production
- Increased IL-12 Production in Splenocytes
- Increased IL-6 Levels in Early Phase
- Increased IPA Levels
- Increased IgA Production by PPs
- Increased IgA-Inducing Activity
- Increased IgA-Secreting Lymphocytes in the Mucosa
- Increased Ileal Enterobacteriaceae Counts
- Increased Ileal Goblet Cell Count
- Increased Ileum Interleukin-10 Levels
- Increased Immune Activation without Cytotoxicity
- Increased Immune Marker Levels
- Increased Immune System Activation
- Increased Immunoglobulin A (IgA) Production
- Increased Immunoglobulin A (IgA)-Positive Cells
- Increased Immunoglobulin A+ Cells in Small Intestine
- Increased Immunosuppressive Cytokine Production
- Increased Inflammatory Cell Counts
- Increased Inflammatory Mediator Production
- Increased Inflammatory Response
- Increased Interest in Probiotic Supplements
- Increased Interleukin 12 Secretion from Dendritic Cells
- Increased Interleukin-10 Levels
- Increased Interleukin-10 Production
- Increased Interleukin-10 Production in the Gut
- Increased Interleukin-12p40 Production
- Increased Interleukin-8 Expression in the Ileum
- Increased Intestinal Anti-E. coli IgA Levels
- Increased Intestinal Barrier Cytoprotection
- Increased Intestinal Bifidobacteria
- Increased Intestinal Cell Adhesion
- Increased Intestinal Crypt Survival
- Increased Intestinal Epithelial Cell Adhesion
- Increased Intestinal IFN-beta Levels
- Increased Intestinal IgA Levels
- Increased Intestinal IgA Secretion
- Increased Intestinal Inflammatory Response
- Increased Intestinal Lactic Acid Bacteria Count
- Increased Intestinal Lactic Acid Bacteria Population
- Increased Intestinal Lactobacillus sakei Levels
- Increased Intestinal Motility
- Increased Intestinal Mucosal Anti-Salmonella Typhimurium Antibody Titers
- Increased Intestinal Mucosal Immune Response
- Increased Intestinal Neutrophil Levels
- Increased Intestinal Permeability Under Exercise-induced Stress
- Increased Intestinal Retention Safety
- Increased Intestinal Stem Cell Proliferation
- Increased Intestinal T-Cell Count
- Increased Intestinal Transit Rate
- Increased Intraepithelial CD8+ Lymphocytes
- Increased Intraepithelial Leukocyte Levels
- Increased Intrinsic Bifidobacteria Levels
- Increased Jejunal Permeability
- Increased Lacticaseibacillus Abundance
- Increased Lactobacilaceae Levels
- Increased Lactobacilli Colonization in the Gut
- Increased Lactobacillus Levels
- Increased Lactobacillus acidophilus in Crop at 14 Days
- Increased Lactobacillus rhamnosus Presence in Stool
- Increased Levels of Actinobacteria
- Increased Levels of Autochthonous Intestinal Bacteria
- Increased Levels of Bifidobacterium infantis in Feces
- Increased Levels of Indole-3-Lactic Acid
- Increased MUC-2 Levels
- Increased Magnesium Absorption
- Increased Metabolic Activity in the Colon
- Increased Microbial Diversity
- Increased Microbial Richness in the Large Intestine
- Increased Microbial Viability in Human Gut
- Increased Mucosal Adhesion
- Increased Mucosal Anti-Inflammatory Mediator MIF Production
- Increased Paneth Cell Number in Intestinal Crypts
- Increased Persistence of Beneficial Bacterial Species
- Increased Persistence of Bifidobacteria
- Increased Persistence of Probiotics in Fecal Matter
- Increased Plasma Immunoglobulin Levels
- Increased Plasma Serotonin Levels
- Increased Population of Beneficial Gut Bacteria
- Increased Population of Clostridium Histolyticum
- Increased Preference for SCFP-Containing Diet
- Increased Prevalence of Normally Formed Stools
- Increased Pro-inflammatory Cytokine IL-6
- Increased Pro-inflammatory Cytokine Release
- Increased Pro-inflammatory Cytokines in Early Healing Phase
- Increased Probiotic Activity
- Increased Probiotic Bacteria Colonization
- Increased Probiotic Bacterial Survival Through Upper Gastrointestinal Transit
- Increased Probiotic Co-existence
- Increased Probiotic Levels
- Increased Probiotic Tolerance
- Increased Proliferation of Administered Bifidobacteria
- Increased Proportion of Activated T Lymphocytes
- Increased Proportion of Intestinal Goblet Cells
- Increased Proportion of Intestinal Regulatory T Cells
- Increased Proportion of Verrucomicrobia in Gastrointestinal Microbiome
- Increased Protective Fecal Bifidobacteria
- Increased Protective Fecal Bifidobacterial Diversity
- Increased Protozoa Counts
- Increased Regulatory T Cell Expansion
- Increased Regulatory T Cell Frequency
- Increased Regulatory T Cell Induction
- Increased Regulatory T Cell Response
- Increased Regulatory T Cells in Intestinal Mucosa
- Increased Regulatory T-Cells in Mesenteric Lymphoid Nodes
- Increased Relapse-Free Survival in Ulcerative Colitis
- Increased Relative Abundance of Beneficial Microbiota (Lactobacillus)
- Increased Resistance to Simulated Gastrointestinal Conditions
- Increased Rikenellaceae Abundance
- Increased SCFA Butyrate Levels
- Increased SCFA Concentration
- Increased SCFA-Producing Bacteria
- Increased Secretory IgA Level
- Increased Secretory Immunoglobulin A
- Increased Serum Anti-inflammatory Metabolites
- Increased Serum Complement 3 (C3) Levels
- Increased Serum IgA Levels
- Increased Serum IgG2 Levels
- Increased Serum Lysozyme Activity
- Increased Serum Metabolites to Combat Inflammation
- Increased Short Chain Fatty Acids
- Increased Short Chain Fatty Acids (SCFAs) Levels
- Increased Short-Chain Fatty Acid Levels
- Increased Short-Chain Fatty Acid-Producing Bacteria
- Increased Short-Chain Fatty Acid-Producing Gut Flora
- Increased Short-Chain Fatty Acids (SCFAs) Contents
- Increased Specific Probiotic Strains
- Increased Stool Consistency
- Increased Stool Frequency
- Increased Stool IgA Levels
- Increased Stool Immunoglobulin A (IgA)
- Increased Stool Looseness
- Increased Stool Volume
- Increased Susceptibility to Salmonella Infection
- Increased T Cell Activation
- Increased TNF-α Production
- Increased Tight Junction Protein Levels
- Increased Tight Junction Proteins (Claudin-1)
- Increased Tolerance to Gastrointestinal Conditions
- Increased Tolerance to Inflammatory Stimuli
- Increased Tolerogenic Dendritic Cells in the Intestine
- Increased Total Fecal Carboxylic Acids
- Increased Total Fecal SCFAs
- Increased Total Immunoglobulin A (IgA) Levels
- Increased Treg Cell Fraction
- Increased Treg Population in the Small Intestine
- Increased Valeric Acid Levels
- Increased Viable Bifidobacteria Counts
- Increased ZO-1 Production in Ileal Tissues
- Induced Circadian Rhythm-Dependent Short-Chain Fatty Acid Production by Gut Microbiota
- Induced Remission in Ulcerative Colitis
- Induced Th1 Cytokines
- Induction of Th1 Immune Response
- Inflammatory Disease Protection
- Influenced Systemic Immune Response
- Inhibited Autoimmune Activation
- Inhibited Changes in Short-Chain Fatty Acids
- Inhibited IκBα Degradation
- Lack of Sustainable Colonization
- Maintained Bacterial Diversity
- Maintained Colonic Epithelial Barrier Integrity
- Maintained Colorectal Homeostasis
- Maintained Crypt Length
- Maintained Digestive Function
- Maintained Fecal Short Chain Fatty Acid Levels
- Maintained Gastrointestinal Health
- Maintained Gut Health
- Maintained Gut Homeostasis
- Maintained Gut Microbiome Composition
- Maintained Gut Microbiota Diversity
- Maintained Gut Permeability
- Maintained Healthy Gut Environment
- Maintained Intestinal Barrier Function
- Maintained Intestinal Barrier Integrity
- Maintained Intestinal Epithelial Homeostasis
- Maintained Intestinal Immune Tolerance
- Maintained Intestinal Microbial Abundance
- Maintained Intestinal Microbiota Stability
- Maintained Intestinal Villi Integrity
- Maintained Microbiota Equilibrium
- Maintained Mucosa-Associated Immunity
- Maintained Mucosal Barrier Integrity
- Maintained Mucus Barrier Integrity
- Maintained Normal Mucosal Barrier Function
- Maintained Prevotella-Dominant Gut Microbiota
- Maintained Remission in Ulcerative Colitis
- Maintained Short-Chain Fatty Acid Levels During Antibiotic Treatment
- Maintenance of Normal Intestinal Function
- Maintenance of Stable Gut Microbiota Profile
- Maintenance of Therapeutic Probiotic Levels
- Mature Gut Microbiota
- Microbial Community Characterization
- Microbial Group Modulation with Bifidobacterial Reduction
- Microbiome Biomarker of Treatment Response
- Microbiome Remodeling
- Mitigated Microbiota Changes
- Moderate Changes in Gastrointestinal Bacterial Groups
- Modification of Gastrointestinal Microbiome
- Modified Dominant Intestinal Bacterial Taxa
- Modulated Bile Acid Profile in Ileum
- Modulated Colonic Microbiota
- Modulated Gastrointestinal Microbiota
- Modulated Gut Microbial Diversity
- Modulated Gut Microbiome Composition
- Modulated Gut Microbiota
- Modulated Humoral Inflammation
- Modulated IL-18-Related Immune Response
- Modulated Immune Function in Offspring
- Modulated Immune Markers
- Modulated Immune Response
- Modulated Immune System
- Modulated Immune Tolerance
- Modulated Immunoinflammatory Parameters
- Modulated Inflammation and Coagulation Interaction
- Modulated Inflammatory Response
- Modulated Innate Immune Response
- Modulated Intestinal Metabolite Profile
- Modulated Intestinal Microbial Community
- Modulated Intestinal Microbial Taxa
- Modulated Intestinal Microflora Composition
- Modulated Peripheral Immune Response
- Modulated Systemic Th1/Th2 Balance
- Modulation of Colon Epithelium by Lactate
- Modulation of Microbiota Activity
- Neutral Probiotic Delivery Through Digestion
- No Change in C-Reactive Protein
- No Change in Colitis-Induced Inflammation
- No Change in Diarrhea
- No Change in Faecal Butyrate Concentration
- No Change in Fecal Abundance of L34 or LGG
- No Change in Fecal Metabolome
- No Change in Fecal Short-Chain Fatty Acid Concentration
- No Change in Gastrointestinal Survival
- No Change in Intestinal Mucosa Morphology
- No Change in Nutrient Digestibility or Blood/Immune Markers
- No Demonstrated Efficacy for Isolated Bifidobacterium Use
- No Improvement in Gastrointestinal Permeability
- No Increase in Fecal Incontinence
- No Meaningful Change in IL-10
- No Meaningful Change in IL-8
- No Protection Against Salmonella-Induced Inflammation
- No Significant Change in Duration of Gastrointestinal Symptoms
- No Significant Change in Tumor Necrosis Factor Alpha Levels
- No Significant Effect on C-Reactive Protein Levels
- No Worsening of Gastrointestinal Symptoms
- Non-Toxicity to Normal Colon Cells
- Normalized Gut Metabolites
- Normalized Gut Microbiota
- Normalized Intestinal Microbiota
- Normalized Osmotic Pressure in the Large Intestine
- Normalized Stool Consistency
- Normalized Stool Type
- Partial Restoration of Intestinal Cell Proliferation
- Partial Restoration of Intestinal Microbiota
- Potential Probiotic Benefits
- Presence of Lactobacillus rhamnosus in Feces
- Presence of Lactobacillus salivarius CECT5713 in Feces
- Presence of Lactococcus Lactis in Gut Microbiota
- Preserved Colon Goblet Cell Density
- Preserved Endogenous Bifidobacteria Composition
- Preserved Gastrointestinal Histological Structure
- Preserved Gut Microbiota Diversity
- Preserved Mucosal Epithelia
- Prevention of Colitis
- Prevention of Colorectal Cancer
- Prevention of Inflammatory Bowel Disease Characteristics
- Prevention of Intestinal Barrier Damage
- Prevention of Intestinal Dysbiosis
- Probiotic Adherence Variability Based on Host Factors
- Promoted Recovery from Colitis-Associated Dysbiosis
- Promotion of Healthy Gut Microbial Colonization
- Protected Enterocyte Structure
- Protected Epithelial Cells Under Inflammatory Conditions
- Protected Intestinal Health
- Protected Small Intestinal Integrity
- Protection Against Brush Border Damage Induced by Bacteria
- Protection Against Colitis
- Protection Against Gut Tissue Damage
- Protection Against Induced Colitis
- Protection Against Intestinal Epithelial Injury
- Protection of Colonic Mucosa from C. difficile Toxins
- Rapid Galactooligosaccharide Degradation During Gastrointestinal Transit
- Recovered Colon Length
- Recovered Microbiome-associated Dysbiosis
- Recovery of BB-12 from Feces
- Reduced AQP8 Expression in Colon
- Reduced Abdominal Discomfort
- Reduced Abdominal Pain Severity
- Reduced Abdominal Surgery Incidence
- Reduced Abdominal Symptoms
- Reduced Aberrant Crypt Number
- Reduced Aberrant Crypts
- Reduced Abundance of Enterobacteriaceae Species
- Reduced Abundance of Odoribacter
- Reduced Abundance of Pathobionts
- Reduced Abundance of Pro-inflammatory Bacteria
- Reduced Abundance of Proteobacteria
- Reduced Abundance of Streptococcus Bacteroides Enterococcus Veillonella
- Reduced Acetate Production
- Reduced Adipose Tissue Wasting
- Reduced Aggravation of Chronic Inflammation
- Reduced Anti-Enterococcus faecalis IgG Levels
- Reduced Antinutrient Levels
- Reduced Apoptosis of Jejunal Mucosal Cells
- Reduced Bacterial Translocation in Mesenteric Adipose Tissue
- Reduced Bacteroides Abundance
- Reduced Bacteroides Fragilis Group Numbers
- Reduced Beta-Glucuronidase Activity
- Reduced Bifidobacterial Population
- Reduced Bifidobacterium longum
- Reduced Bitter-Related Organic Acids
- Reduced Bowel Discomfort Symptoms
- Reduced Bowel Dysfunction
- Reduced Brachyspira hyodysenteriae Growth
- Reduced Butyrate Production
- Reduced C-Reactive Protein Levels
- Reduced CD4+ T Cell Lymphocytes in Intestinal Mucosa
- Reduced Campylobacter Coli Colonization
- Reduced Campylobacter jejuni Inhibition
- Reduced Campylobacter jejuni Survival
- Reduced Circulating Endotoxin
- Reduced Clinical Relapse Rates
- Reduced Clinical Symptoms of Colitis
- Reduced Clostridia Cluster XIV
- Reduced Clostridia Counts
- Reduced Clostridium Counts
- Reduced Clostridium Species Numbers
- Reduced Coliform Levels in the Jejunum
- Reduced Colitis Development
- Reduced Colitis Inflammation
- Reduced Colitis Recurrence
- Reduced Colitis Risk
- Reduced Colitis Severity
- Reduced Colitis Symptoms
- Reduced Colitis-Associated Weight Loss
- Reduced Colitis-Related Mortality
- Reduced Colon Cancer Risk
- Reduced Colon Length
- Reduced Colon Pain
- Reduced Colon Shortening
- Reduced Colonic Atrophy
- Reduced Colonic Clostridium Species
- Reduced Colonic Damage
- Reduced Colonic Enterobacteriaceae Species
- Reduced Colonic Inflammation
- Reduced Colonic Microscopic Damage
- Reduced Colonic Mucosa Damage
- Reduced Colonic Myeloperoxidase Levels
- Reduced Colonic Oxidative Damage
- Reduced Colonic Pathology
- Reduced Colonic Permeability
- Reduced Colonic Transit Time
- Reduced Colonisation of Lactobacillus casei Strain Shirota
- Reduced Colonization by Diarrheagenic E. coli (EPEC)
- Reduced Colonization of Cronobacter sakazakii in Enterocytes
- Reduced Colorectal Cancer Risk Associated with Ulcerative Colitis
- Reduced Colorectal Tumorigenesis
- Reduced Constipation Incidence
- Reduced Copper Level
- Reduced Crohn's Disease Symptoms
- Reduced Crypt Cell Proliferation
- Reduced Crypt Depth
- Reduced Cyclooxygenase-2 Levels
- Reduced Cytokine Production in Colonic Epithelial Cells
- Reduced Cytokine Response
- Reduced Cytotoxic T Cells in Peyer's Patches
- Reduced Days with Defecation Urgency
- Reduced Days with Diarrhea
- Reduced Defense Gene Activity for Gram-Negative Pathogens
- Reduced Deferribacteres in Gut Microbiota
- Reduced Detection Rates of Clostridium
- Reduced Diarrhea
- Reduced Diarrhea Episodes
- Reduced Diarrhea Frequency
- Reduced Diarrhea Severity
- Reduced Diarrhea Symptoms
- Reduced Digestive Symptoms
- Reduced Disease Activity
- Reduced Disease Activity Index (DAI) Levels
- Reduced Disease Activity Index Scores
- Reduced Disease Activity Index in Colitis Model
- Reduced Disease Activity in Colitis
- Reduced Disease Activity in Ulcerative Colitis
- Reduced Duration of Gastrointestinal Symptoms
- Reduced Dysbiosis
- Reduced E. coli Activity
- Reduced EHEC Colonization
- Reduced Effects of Inflammatory Bowel Disease
- Reduced Elevated Immune Cells in Mesenteric Lymph Nodes
- Reduced Enteritis
- Reduced Enteritis Index
- Reduced Enterobacteria Levels
- Reduced Enterobacteriaceae Counts
- Reduced Enterobacteriaceae Levels in Feces
- Reduced Enterobacteriaceae in Intestines
- Reduced Enterocyte Damage
- Reduced Enterocyte Injury from Capsaicin
- Reduced Enterocyte Layer Colonization by Salmonella enterica
- Reduced Enteropathy
- Reduced Epithelial Barrier Disruption
- Reduced Epithelial Permeability
- Reduced Escherichia Abundance
- Reduced Escherichia Vulneris Abundance
- Reduced Expression of Caspase-1 in Ileum
- Reduced Expression of Proinflammatory Mediators
- Reduced FITC-Dextran Flux Upregulation
- Reduced Faecal Calprotectin
- Reduced Faecal Levels of Total Lactobacillus Species
- Reduced Faecal pH
- Reduced Fecal Acetate
- Reduced Fecal Bacterial Enzyme Activity
- Reduced Fecal Bacterial Nitroreductase Activity
- Reduced Fecal Calprotectin Immunoglobulin A
- Reduced Fecal Calprotectin Levels
- Reduced Fecal Clostridium Levels
- Reduced Fecal Coliform Count
- Reduced Fecal Enterobacilli
- Reduced Fecal Escherichia coli Levels
- Reduced Fecal Excretion of Bacteroides Fragilis
- Reduced Fecal Hydrogen Sulfide Emissions
- Reduced Fecal Immune Biomarkers
- Reduced Fecal Loading
- Reduced Fecal Metabolite Levels
- Reduced Fecal Microbiota Diversity
- Reduced Fecal Score
- Reduced Fecal Secondary Bile Acid Contents
- Reduced Fecal p-Cresol Levels
- Reduced Flavonifractor Abundance
- Reduced Fluid Secretion in the Ileum
- Reduced Fungal Enteric Colonization
- Reduced Fusobacterium Nucleatum Levels
- Reduced GLP-1 Receptor Positive Cells in Colon
- Reduced Gastric Polyamine Levels
- Reduced Gastrointestinal Adverse Events
- Reduced Gastrointestinal Discomfort Symptoms
- Reduced Gastrointestinal Disease Incidence in Children
- Reduced Gastrointestinal Disease Symptoms
- Reduced Gastrointestinal Disorder Symptoms
- Reduced Gastrointestinal Disorders
- Reduced Gastrointestinal Inflammation
- Reduced Gastrointestinal Leakage
- Reduced Gastrointestinal Symptom Rating Scale Score
- Reduced Gastrointestinal Symptom Severity
- Reduced Gastrointestinal Symptoms
- Reduced Gastrointestinal Symptoms Score
- Reduced Gastrointestinal Tract Histological Damage
- Reduced Gemmiger formicilis Abundance
- Reduced Genera Romboutsia
- Reduced Groalpha Secretion
- Reduced Gut Barrier Defect
- Reduced Gut Damage
- Reduced Gut Disorders
- Reduced Gut Humoral Proinflammatory Response
- Reduced Gut IFN-γ Production
- Reduced Gut Inflammation
- Reduced Gut Leakage
- Reduced Gut Membrane Barrier Damage
- Reduced Gut Permeability
- Reduced Gut Proteobacteria
- Reduced Hard Stool
- Reduced Harmful Gut Bacteria
- Reduced Harmful Gut Microbiota
- Reduced Harmful Intestinal Bacteria
- Reduced Harmful Intestinal Metabolites
- Reduced Histologic Remission
- Reduced Histological Damage Scores
- Reduced Humoral Immunity to Bacteroides thetaiotaomicron
- Reduced IBD Symptoms
- Reduced IBS Severity
- Reduced IFN-γ in Serum
- Reduced IL-10 Expression in Ileum
- Reduced IL-12p70 Release
- Reduced IL-17 Production in Splenocytes
- Reduced IL-18 Expression in Ileum
- Reduced IL-1β Expression in Ileum
- Reduced IL-6 Concentration
- Reduced IL-6 Production
- Reduced IL-8 Secretion
- Reduced IL6 Production in Intestinal Epithelial Cells
- Reduced Ileal Malondialdehyde (MDA) Levels
- Reduced Ileal Oxidative Damage
- Reduced Immune Activation
- Reduced Immunoinflammatory Markers
- Reduced Impact on Existing Indigenous Microbiota
- Reduced Incidence of Acute Colitis
- Reduced Incidence of Chronic Diarrhea
- Reduced Incidence of Chronic Inflammatory Diseases in Smokers
- Reduced Incidence of Colon Cancer
- Reduced Incidence of Gastrointestinal Adverse Events
- Reduced Incidence of Inflammatory Bowel Diseases
- Reduced Incidence of Loose or Watery Stools
- Reduced Incidence of Ulcers
- Reduced Incidence of Watery Diarrhea
- Reduced Indigenous Enterobacteria Colonization
- Reduced Inducible Nitric Oxide Synthase Expression in Intestinal Tissue
- Reduced Infection Frequency
- Reduced Inflammation
- Reduced Inflammation Levels
- Reduced Inflammation Markers
- Reduced Inflammation from Salmonella Typhimurium
- Reduced Inflammation in Dendritic Cells
- Reduced Inflammation in Inflammatory Bowel Disease
- Reduced Inflammation in Intestinal Enterocytes
- Reduced Inflammation in Premature Intestinal Cells
- Reduced Inflammation via Gut Microbiota
- Reduced Inflammatory Activities
- Reduced Inflammatory Bowel Disease Symptoms
- Reduced Inflammatory Cell Activity
- Reduced Inflammatory Cytokine Secretion from Activated T Cells
- Reduced Inflammatory Cytokines (TNF-α, IFN-γ, IL-6)
- Reduced Inflammatory Diseases
- Reduced Inflammatory Immune Mediators
- Reduced Inflammatory Injury
- Reduced Inflammatory Markers
- Reduced Inflammatory Markers in Ulcerative Colitis
- Reduced Inflammatory Mediators
- Reduced Inflammatory Parameters
- Reduced Inflammatory Pathway Activity
- Reduced Inflammatory Pathways
- Reduced Inflammatory Processes
- Reduced Inflammatory Protein Activation
- Reduced Inflammatory Response
- Reduced Inflammatory Response in Intestinal Cells
- Reduced Inflammatory Response to Inflammatory Stimulus
- Reduced Inflammatory Stimulators
- Reduced Inflammatory Tone
- Reduced Injury-Induced Gut Inflammation
- Reduced Interleukin Level
- Reduced Interleukin-10 Levels
- Reduced Interleukin-22 Level
- Reduced Interleukin-8 Levels
- Reduced Interleukin-8 Secretion
- Reduced Intestinal Aging
- Reduced Intestinal Apoptosis
- Reduced Intestinal Cell Adhesion
- Reduced Intestinal Cell Death
- Reduced Intestinal Damage
- Reduced Intestinal Epithelial Apoptosis
- Reduced Intestinal Histological Damage
- Reduced Intestinal Hyperpermeability
- Reduced Intestinal Immune Cell Count
- Reduced Intestinal Immunopathology
- Reduced Intestinal Inflammation
- Reduced Intestinal Inflammation Severity
- Reduced Intestinal Lesion Scores
- Reduced Intestinal Mucosal Immune Response
- Reduced Intestinal Myeloperoxidase Level
- Reduced Intestinal NE Lesion Score
- Reduced Intestinal Oxidative Damage
- Reduced Intestinal Pathogen Prevotella
- Reduced Intestinal Pathology
- Reduced Intestinal Pathology Changes
- Reduced Intestinal Permeability
- Reduced Intestinal Permeability Defect
- Reduced Intestinal Proinflammatory Cytokine Levels
- Reduced Intestinal Salmonella Burden
- Reduced Intestinal Tissue Damage
- Reduced Intestinal Tissue Injury
- Reduced Intestinal Transit Time
- Reduced LPS Translocation
- Reduced LPS-Induced Inflammation
- Reduced Lesion Size
- Reduced Levels of Pro-Inflammatory Cytokines (IL-1β, IL-6, IFN-γ, TNF-α)
- Reduced Lipid Peroxidation in Colonic Mucosa
- Reduced Listeria Colonization
- Reduced Local Inflammation
- Reduced Low-grade Intestinal Inflammation
- Reduced Lower Intestinal pH
- Reduced Macromolecule Permeability
- Reduced Methanobrevibacter Levels
- Reduced Microbial Translocation
- Reduced Morphological Damage of the Jejunum
- Reduced Mucin Gene Transcription
- Reduced Mucosal Adherent Citrobacter rodentium
- Reduced Mucosal Cytokine Response
- Reduced Mucosal Damage
- Reduced Mucosal Inflammation
- Reduced Mucosal Permeability
- Reduced Mucosal Pro-Inflammatory Activity
- Reduced Mucosal Thickness
- Reduced Neurally Evoked Ion Secretion in the Colon
- Reduced Neutrophil Extracellular Trap Formation
- Reduced Neutrophil Recruitment
- Reduced Occurrence of Soft Stools
- Reduced Oral Aphthosis Frequency
- Reduced Oxidative Stress in Ileum Mucosa
- Reduced Oxidative Stress in Intestinal Epithelial Cells
- Reduced Painful Defecation
- Reduced Pathogen Translocation to Visceral Tissues
- Reduced Pathological Characteristics of the Intestinal Tract
- Reduced Percentage of Bacteroidaceae in Gut Microbiota
- Reduced Peripheral Inflammation
- Reduced Phospho-p65 Translocation
- Reduced Plasma IL-10 Levels
- Reduced Plasma Vitamin K Levels
- Reduced Population of Fusobacterium prausnitzii
- Reduced Prevalence of Iron Deficiency
- Reduced Prevalence of Proteobacteria
- Reduced Pro-Inflammatory Bacteria Levels
- Reduced Pro-Inflammatory Cells
- Reduced Pro-Inflammatory Cytokine Interleukin-15 Levels
- Reduced Pro-Inflammatory Cytokine Synthesis
- Reduced Pro-Inflammatory Cytokines
- Reduced Pro-Inflammatory Factor TNF-α
- Reduced Pro-Inflammatory Immune Activity
- Reduced Pro-Inflammatory Mediator Production
- Reduced Pro-inflammatory Cytokine Expression in Ileum
- Reduced Pro-inflammatory Cytokine Interleukin-8 Levels
- Reduced Pro-inflammatory Cytokine Levels
- Reduced Pro-inflammatory Cytokine Production in LPS-stimulated Cells
- Reduced Pro-inflammatory Effect
- Reduced Pro-inflammatory Gene Transcription
- Reduced Pro-inflammatory Immune Responses
- Reduced Pro-inflammatory Mediator Levels
- Reduced Proinflammatory Cytokine Secretion
- Reduced Proinflammatory Cytokines Gene Transcription
- Reduced Proinflammatory Cytokines in Middle-aged Adults
- Reduced Proinflammatory Factor Levels
- Reduced Proinflammatory Factors
- Reduced Proinflammatory Mediators
- Reduced Proinflammatory Profile
- Reduced Prolonged Diarrhea
- Reduced Proportion of Patients with Loose Stools
- Reduced Proportion of Proteobacteria
- Reduced Radiological Damage in the Gut
- Reduced Recurrence Risk
- Reduced Recurrent Clostridioides difficile Infection Incidence
- Reduced Red Blood Cell Folate Concentration
- Reduced Relapse Rate
- Reduced Relative Abundance of Bacteroidales
- Reduced Relative Abundance of Coriobacteriaceae
- Reduced Relative Abundance of Escherichia-Shigella
- Reduced Relative Abundance of Sutterella
- Reduced Release of Inflammatory Mediators (TNF-α, IL-6, IL-1β, IL-10)
- Reduced Richness Indicators in Ileum
- Reduced Risk of Chronic Inflammatory Diseases
- Reduced Risk of Prolonged Diarrhea
- Reduced Ruminococcus Abundance
- Reduced S. Enteritidis Invasion
- Reduced S. Typhimurium Infection
- Reduced Salmonella Activity
- Reduced Salmonella Translocation
- Reduced Salmonella Typhimurium Activity
- Reduced Secretory IgA Content in Faeces
- Reduced Secretory Immunoglobulin A in Stools
- Reduced Sellimonas Abundance
- Reduced Sensitivity to Tetrodotoxin (TTx) Inhibition in Short-circuit Current Response
- Reduced Serum Anti-Lactic Acid Bacteria IgA Levels
- Reduced Serum Cytokine Levels
- Reduced Serum Diamine Oxidase Activity
- Reduced Serum Endotoxin Level
- Reduced Serum Inflammatory Factors
- Reduced Serum LPS Levels
- Reduced Serum TNF-Alpha Level
- Reduced Serum TNF-α Levels
- Reduced Serum Tumor Necrosis Factor-α
- Reduced Severe Necrotizing Enterocolitis (NEC)
- Reduced Severity of Acute Colitis
- Reduced Severity of Chemotherapy-Induced Enteropathy
- Reduced Severity of Colon Lesions
- Reduced Short-Chain Fatty Acid Levels in Feces
- Reduced Short-Chain Fatty Acid Levels in the Colon
- Reduced Small-intestinal Ulcers
- Reduced Steroid Load
- Reduced Steroid Usage
- Reduced Stool Consistency
- Reduced Stool pH
- Reduced Stress-Induced Intestinal Hyperpermeability
- Reduced Sulphite-Reducing Clostridia
- Reduced Susceptibility to Enteric Infection
- Reduced Susceptibility to Inflammatory Exposure
- Reduced Swede Score
- Reduced Symptoms of Oral Aphthous Ulcers
- Reduced Systemic Inflammatory Response
- Reduced T-Effector Memory Cell Activity
- Reduced TNF Production
- Reduced TNF-alpha Level
- Reduced TNF-α Concentration
- Reduced TNF-α Levels
- Reduced TNF-α Levels in Mesenteric Lymph Nodes
- Reduced TNF-α Signaling
- Reduced Th17/Tregs Cell-Differentiation Ratio in Mesenteric Lymph Nodes
- Reduced Threonine
- Reduced Time Spent for Defecation
- Reduced Tissue Damage from Colitis
- Reduced Transepithelial Resistance
- Reduced Tumor Necrosis Factor Alpha Production
- Reduced Tumor Necrosis Factor-α (TNF-α)
- Reduced Tumor Necrosis Factor-α Levels
- Reduced Turicibacter Abundance
- Reduced Ulcer Symptoms
- Reduced Ulcerative Colitis Symptoms
- Reduced Urgency of Bowel Movements
- Reduced Urinary Oxalate Excretion
- Reduced Valeric Acid Levels
- Reduced Villus Height
- Reduced Visceral Pain
- Reduced Weight Loss in Colitis Mice
- Reduced Yersinia Pseudotuberculosis Invasion
- Reestablished Intestinal Microecology
- Regression of Gastrointestinal Disorders
- Regulated Colonic Bacterial Flora
- Regulated Cytokine Levels
- Regulated Gastrointestinal Function
- Regulated Host Epithelial Cells
- Regulated Immune Cell Proliferation
- Regulated Immune Response
- Regulated Inflammation
- Regulated Inflammatory Cytokines
- Regulated Inflammatory Markers
- Regulated Inflammatory Responses
- Regulated Intestinal Barrier Function
- Regulated Intestinal Microbiota
- Regulated Intestinal Microbiota Balance
- Regulated Intestinal Microorganisms
- Regulated Systemic Immune Response Imbalance
- Relief from Rectal Tearing or Bleeding After Bowel Movement
- Relieved Gastrointestinal Symptoms
- Relieved Intestinal Impairments
- Remodeled Intestinal Microbiota
- Repaired Colon Tissue
- Requirement for Sustained Dosage in Gastrointestinal Tract
- Restored Aggregation Phenotype and Protective Effect on Colitis
- Restored Barrier Function
- Restored Colonic Water Transport
- Restored Goblet Cell Count
- Restored Gut Microbiome Balance
- Restored Gut Microbiota Diversity
- Restored Gut Microbiota Homeostasis
- Restored Gut Microbiota Structure
- Restored Immune Organ Structure
- Restored Intestinal Barrier Function
- Restored Intestinal Microbiota Balance
- Restored Intestinal Structure
- Restored Microbial Diversity
- Restored Microbiome Composition
- Restored Mucin-2 Levels
- Restored Mucus Layer Integrity
- Restored Protective Effect in Colitis
- Restored Regulatory T Cell Population
- Restored Regulatory T Cell Population in Mesenteric Lymph Nodes
- Restored Short-Chain Fatty Acid Levels
- Restored Treg Cell Population in MLNs
- Reversed Microbiome Metabolic Changes
- Reversed Toxin-Induced Inhibition of Protein Synthesis in Colonic Cells
- Safety of Probiotic Supplementation
- Stabilized Fecal Dry Matter Percentage
- Stabilized Fecal Secondary Bile Acids
- Stabilized Gut Microbiota
- Stabilized Intestinal Microbiota
- Stable Bowel Function
- Stable Cytokine Levels in Gut-Associated Lymphoid Tissue
- Stable Fecal pH
- Stable Immune System Responses
- Stable Inflammatory Responses
- Stable Proinflammatory Cytokine Levels
- Successful Gut Colonization
- Suppressed Enterobacteriaceae Levels
- Suppressed TNF-α Induced Genes
- Survival Through Human Intestine
- Sustained Bifidobacteria Populations
- Tolerance to Lactobacillus rhamnosus PRSF-L477
- Unchanged Colonic Transit Time
- Unchanged Fecal Antibiotic Resistance
- Unchanged Fecal IgA Levels
- Unchanged Gastrointestinal Resistance
- Unchanged Gastrointestinal Symptoms
- Unchanged Gut Microbiota Diversity
- Unchanged Intestinal Bacterial Concentrations
- Unchanged Severe Diarrhea
- Unchanged Stool Consistency or Bowel Frequency
- Unchanged Stool Frequency
- Viability of Probiotic Bacteria in Cheese
- Worsened Autoimmune Manifestations
- Worsened Fecal Scores